» Articles » PMID: 21437064

Management of Tinea Capitis in Childhood

Overview
Publisher Dove Medical Press
Specialty Dermatology
Date 2011 Mar 26
PMID 21437064
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Tinea capitis (TC) is a common dermatophyte infection affecting primarily prepubertal children. The causative pathogens belong to only two genera: Trichophyton and Microsporum. Although there is a great local variation in the epidemiology of TC worldwide, T. tonsurans is currently the most common cause of TC with M. canis second. Even though there is an emerging number of anthropophilic scalp infections, M. canis remains the predominant causative organism in many countries of the Mediterranean basin, the most important dermatophyte carriers being stray cats and dogs as well as pet puppies, kittens and rabbits. TC always requires systemic treatment because topical antifungal agents do not penetrate down to the deepest part of the hair follicle. Since the late 1950s, griseofulvin has been the gold standard for systemic therapy of TC. It is active against dermatophytes and has a long-term safety profile. The main disadvantage of griseofulvin is the long duration of treatment required which may lead to reduced compliance. The newer oral antifungal agents including terbinafine, itraconazole, ketokonazole, and fluconazole appear to have efficacy rates and potential adverse effects similar to those of griseofulvin in children with TC caused by Trichophyton species, while requiring a much shorter duration of treatment. They may, however, be more expensive.

Citing Articles

Epidemiology, clinical features, and outcome of the hospitalized patients with Kerion in Fars Province, Iran: an eleven-year retrospective study.

Khosravi F, Parvizi M, Sadati M, Khosravi M, Ghahartars M BMC Pediatr. 2024; 24(1):694.

PMID: 39482618 PMC: 11526556. DOI: 10.1186/s12887-024-05171-6.


Dermoscopic findings in Tinea Capitis among under 18 children in dermatology polyclinic patients: a hospital-based cross-sectional study.

Ali A, Aden A, Mohamud A Ann Med Surg (Lond). 2024; 86(1):121-126.

PMID: 38222710 PMC: 10783287. DOI: 10.1097/MS9.0000000000001530.


Tinea capitis caused by in an immunocompetent elderly patient: A case report and review of literature.

Gheisari M, Zahedi K, Al-Zubaidi N Clin Case Rep. 2023; 11(11):e8205.

PMID: 38028093 PMC: 10661301. DOI: 10.1002/ccr3.8205.


Antifungal Activity of N-Arylbenzoquinaldinium Derivatives against a Clinical Strain of .

Shchepina N, Alexandrova G, Balandina S, Boiko I, Chaudhary S, Shchepin R Indian J Dermatol. 2023; 68(4):487.

PMID: 37822376 PMC: 10564204. DOI: 10.4103/ijd.IJD_261_16.


Retrospective Analysis of Tinea Capitis in Xinjiang, China.

Wang X, Abuliezi R, Hasimu H, Zhang L, Abliz P Mycopathologia. 2023; 188(5):523-529.

PMID: 37012555 DOI: 10.1007/s11046-022-00702-0.


References
1.
Honig P, Caputo G, Leyden J, McGinley K, Selbst S, McGravey A . Treatment of kerions. Pediatr Dermatol. 1994; 11(1):69-71. DOI: 10.1111/j.1525-1470.1994.tb00079.x. View

2.
Seebacher C, Abeck D, Brasch J, Cornely O, Daeschlein G, Effendy I . Tinea capitis: ringworm of the scalp. Mycoses. 2007; 50(3):218-26. DOI: 10.1111/j.1439-0507.2006.01350.x. View

3.
Elewski B, Caceres H, DeLeon L, El Shimy S, Hunter J, Korotkiy N . Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. J Am Acad Dermatol. 2008; 59(1):41-54. DOI: 10.1016/j.jaad.2008.02.019. View

4.
Dastghaib L, Azizzadeh M, Jafari P . Therapeutic options for the treatment of tinea capitis: griseofulvin versus fluconazole. J Dermatolog Treat. 2005; 16(1):43-6. DOI: 10.1080/09546630510025932. View

5.
Hussain I, Muzaffar F, Rashid T, Ahmad T, Jahangir M, Haroon T . A randomized, comparative trial of treatment of kerion celsi with griseofulvin plus oral prednisolone vs. griseofulvin alone. Med Mycol. 1999; 37(2):97-9. View